Comparison of safety and efficacy of 250 μg roflumilast versus 500 μg roflumilast versus placebo over 12 weeks in patients with chronic obstructive pulmonary disease (COPD)

Study identifier:BY217/IN-108

ClinicalTrials.gov identifier:N/A

EudraCT identifier:

CTIS identifier:N/A

Study Complete

Official Title

*Please Note* The Study you are attempting to view was acquired from Takeda by AstraZeneca and was disclosed initially by Takeda per their Transparency Policies. More information regarding this study may be available by contacting [email protected].

Medical condition

Chronic Obstructive Pulmonary Disease

Phase

Phase 2

Healthy volunteers

Study drug

Sex

All

Actual Enrollment

118

Study type

Interventional

Age

40 Years - 75 Years

Date

Study Start Date: 01 Aug 2002

Primary Completion Date: -

Study Completion Date: 01 Jul 2003

Study design

Allocation: -
Endpoint Classification: -
Intervention Model: -
Masking: -
Primary Purpose: -

Verification:

Verified 01 Jun 2016 by Takeda

Collaborators

Inclusion and exclusion criteria

No locations available

Arms	Assigned Interventions

Documents available

BY217-IN-108-RDS-2014-10-26.pdf
Download
Trial Results Summaries
Available here

Contacts

Contact

AstraZeneca Clinical Study Information Center

1-877-240-9479

[email protected]